Organization and Business - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended		71 Months Ended			3 Months Ended		3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Dec. 31, 2011	Mar. 31, 2013	Dec. 31, 2012	May 09, 2007	Jun. 30, 2013 Subsequent Event	Mar. 31, 2013 Phase I clinical trial	Mar. 31, 2013 Phase I clinical trial Minimum y	Mar. 31, 2013 Phase I clinical trial Maximum y
Organization and Nature of Operations [Line Items]
Number of evaluable patients in Phase I Clinical trial										18	30
Number patients benefited from Liposomal Grb-2 treatment									3
Percentage of Charge				50.00%
Impairment of License	$ 0	$ 0		$ 345,000	$ 690,000
Cash	288,707	576,823	288,707	952,252	288,707	534,046	0
Carrying value of the siRNA license	345,000
Proceeds from issuance of private placement			$ 4,000,000					$ 2,260,000